Item 8.01 Other Events.
On April 20, 2021, bluebird bio, Inc. (the "Company") issued a press release
announcing business and program updates across its severe genetic disease
portfolio including a revised diagnosis of transfusion-dependent anemia for a
case that was initially reported as myelodysplastic syndrome (MDS) in the
HGB-206 study of LentiGlobin for sickle cell disease (bb1111), removal of
Zynteglo (betibeglogene autotemcel, beti-cel) for ?-thalassemia from the German
market due to the outcome of reimbursement negotiations in Germany, and a
reduction in workforce intended to enable the Company to advance its late-stage
gene therapy programs.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press release issued by bluebird bio, Inc. on April 20 , 2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses